Dr. Alison Grann, MD

Dr. Grann practices at Cooperman Barnabas Medical Center in Livingston, New Jersey, part of RWJBarnabas Health.

Dr. Grann's NPI, 1992751853, was assigned on May 25, 2006. Dr. Grann graduated from George Washington University School of Medicine and Health Sciences in 1991. Dr. Grann holds New Jersey license MA07133.

Dr. Grann's primary practice is Cooperman Barnabas Medical Center, at 94 Old Short Hills Road, Livingston, NJ 07039 in Essex County. The practice phone is (973) 322-5000.

Dr. Grann's primary practice is Cooperman Barnabas Medical Center in Livingston, New Jersey, part of RWJBarnabas Health. Dr. Grann is also affiliated with Morristown Medical Center. The medical group on file is RWJBarnabas Health Medical Group.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Grann practices, 2 sites in all. Vendor and product names are available with a free account.

Therapeutic radiology is Dr. Grann's primary specialty in the NPI Registry, under taxonomy code 2085R0203X. Dr. Grann is board certified in radiation oncology by the American Board of Radiology. Dmand AI has Dr. Grann's licenses on file in 2 states: New Jersey and New York.

Dmand AI lists bone cancer radiation, breast cancer radiation and prostate cancer radiation among the conditions Dr. Grann treats.

CMS data shows 1,099 Medicare services from Dr. Grann across 14 procedure codes in 2024, for 228 Medicare patients. Medicare paid $95,399 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 228 Medicare patients who saw Dr. Grann in 2024. The largest group is 65 to 74, with 115 patients. 75% of them have cancer, and 75% have high blood pressure. Their average risk score is 1.21, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Grann's median patient age at 72, with 68% women.

In 2024, Dr. Grann wrote 140 Medicare Part D claims for 52 patients. 99% of them were for generic drugs. CMS names the drug for 107 of them, across 2 drugs with 11 or more claims each, at $1,846 in total drug cost.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 99 out of 100 for Dr. Grann for performance year 2024, reported through an alternative payment model (APM). Dr. Grann accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 18 papers to Dr. Grann, published from 2007 to 2024. 2020 was the busiest year, with 2. The most frequent topics are Adenocarcinoma, Brachytherapy and Preoperative Care. Dr. Grann has published most often in Int J Radiat Oncol Biol Phys. Dr. Grann's most frequent co-authors are Raquel Tamara Wagman, MD, Bruce G. Haffty, MD and Lara Hathout.

Dmand AI links Dr. Grann to 2 clinical trials. 2 are still active or recruiting. Conditions studied include Breast Neoplasms, Carcinoma, Lobular and Breast Diseases.

CMS Open Payments shows 5 general payments to Dr. Grann from 4 drug and device companies from 2024 to 2025. Food and beverage make up the largest share, 100% of the total. GT Medical Technologies, Inc paid the most, $102.

Dmand AI lists 5 awards for Dr. Grann, most recently Inside Jersey Magazine Top Doctors in 2014. Dr. Grann serves on Institutional review board and Medical executive committee.

Dr. Grann graduated from George Washington University School of Medicine and Health Sciences in 1991. Dr. Grann is a member of ASTRO and ASCO.

Dr. Grann is in network with 16 carriers, including Elevance, Aetna and Blue Cross Blue Shield of Michigan. PPO plans come from the most carriers, 11. Check the plan with the practice before a visit.